Top 10 Pharma Drug Discovery Delivery Capital Raises and Investors in the U.S. – November 16th – December 31st, 2025
Several interesting transactions closed in the Pharma Drug Discovery Delivery sector over the past month. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
Buyout/LBO
- Surmodics, performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays, was acquired by GTCR through a $626.85 million public-to-private LBO.
Later Stage VC
- Aeovian Pharmaceuticals, biotechnology therapies that address inflammatory and degenerative diseases, raised $55 million of Series B venture funding in a deal led by CTI Life Sciences Fund and Luma Group.
- Imbria Pharmaceuticals, novel therapies for patients with life-altering cardiometabolic disorders, raised $66.70 million of Series B venture funding in a deal led by Deep Track Capital.
- Mend, clinical nutritional products that assist people in healing and living a quality life, raised $20.45 million of Series A venture funding led by S2G Investments.
- ProLynx, ultra-long-acting medicines for obesity and other metabolic diseases, raised $70 million through a combination of Series A-1, Series A-2, and Series A-3 venture funding in a deal led by OrbiMed and 5AM Ventures.
- Vitrivax, thermostable vaccine formulations that eliminate barriers to global vaccination, raised $29.43 million through a combination of Series B-1 and Series B-2 venture funding in a deal led by RA Capital Management and Adjuvant Capital.
Early Stage VC
- Addition Therapeutics, biotech and pharmaceutical research company that transforms genetic medicine, raised $106.5 million of venture funding from Abingworth, SR One Capital Management and Osage University Partners.
- Quarry Thera, proximity-driven therapeutics that overcomes limitations in conventional drug modalities, raised $32 million of Series A venture funding from Eli Lilly, Yosemite and Canaan Partners.
- Solve Therapeutics, drug development platform that develops novel antibody-drug conjugates, raised $321 million of Series A venture funding in a deal led by Yosemite.
Seed Round
- Juniper Biosciences, therapeutic and diagnostic agents intended for precision healthcare and disease management purposes, raised $40 million of seed funding in a deal led by Nova Capital.
#castleplacement #capitalraising #privateequity #venturecapital #investment #pharma #drug #drugdiscovery #drugdelivery
Diana Ruddy
Managing Director
Over 20 years of diverse experience in investment banking, consulting, and commercial lending. Developed transactions up to $350 million, sourcing debt and equity funding for domestic and international projects across a wide range of industries. Advised companies on expansion, mergers and acquisitions, financial structure, contract negotiation, and strategic planning. Industry experience includes healthcare, technology, energy, aviation, real estate, manufacturing, retail, agriculture, hospitality, financial services, and nonprofits. Bachelor of Science with highest honors in Finance from UMass Boston, and MBA with great distinction from Arizona State University W.P. Carey School of Business. FINRA Series 7, 66, 79 and 99 licenses.
- Email: druddy@castleplacement.com
- (C) (406) 868-3218
Diana Ruddy
Managing Director
Please contact me if you have any questions or would like to discuss your capital raise:
Email: druddy@castleplacement.com
(C) (406) 868-3218
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
